Pasithea Therapeutics (KTTA) Payables (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Payables for 4 consecutive years, with $660397.0 as the latest value for Q3 2024.
- Quarterly Payables fell 64.67% to $660397.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $660397.0 through Sep 2024, down 64.67% year-over-year, with the annual reading at $2.6 million for FY2023, 72.29% up from the prior year.
- Payables hit $660397.0 in Q3 2024 for Pasithea Therapeutics, down from $1.4 million in the prior quarter.
- In the past five years, Payables ranged from a high of $2.6 million in Q4 2023 to a low of $405893.0 in Q1 2023.
- Historically, Payables has averaged $1.3 million across 4 years, with a median of $1.3 million in 2022.
- Biggest YoY gain for Payables was 499.66% in 2024; the steepest drop was 64.67% in 2024.
- Year by year, Payables stood at $447280.0 in 2021, then skyrocketed by 231.2% to $1.5 million in 2022, then soared by 72.29% to $2.6 million in 2023, then tumbled by 74.13% to $660397.0 in 2024.
- Business Quant data shows Payables for KTTA at $660397.0 in Q3 2024, $1.4 million in Q2 2024, and $2.4 million in Q1 2024.